NCT Number: NCT05332184
Cardiac T1 Mapping Enables Risk Prediction of LV Dysfunction After Surgery for Aortic Regurgitation
To assess whether cardiac T1 mapping for detection of myocardial fibrosis enables preoperative identification of patients at risk for early left ventricular dysfunction after surgery of aortic regurgitation.
Looking for future studies?
Notify MeKey information
Conditions
Sex eligibility
All sexes
Study type
Observational
About this study
We hypothesized that a diffuse interstitial myocardial fibrosis may be present in AR patients who experience early systolic LV dysfunction after aortic valve surgery. We aimed to evaluate the association between preoperative cardiac T1 mapping for detection of myocardial fibrosis and early systolic LV dysfunction after surgery for aortic regurgitation.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Consecutive patients with severe aortic regurgitation referred for aortic valve surgery were prospectively enrolled in the study.
Exclusion criteria
- history of coronary artery disease
- acute aortic valve disease (i.e., type A aortic dissection or infectious endocarditis)
- common contraindications for MRI such as severe obesity and metallic foreign bodies.
Treatment and study plan
Primary outcomes
-
Native T1
Time frame: baseline (Prior surgery)
Measured with MRI
Sponsors and collaborators
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf
Other
Registry information
Important dates
- Study start
- 2016
- Primary completion
- 2019
- Study completion
- 2020
- First posted
- Apr 18, 2022
- Registry last updated
- Apr 18, 2022
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
China S3: Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 THV in the Chinese Population
NCT03466918
Aortic Regurgitation, Aortic Stenosis
Beijing, China
View Trial DetailsThe Fate of Aortic Valve After SAS Surgery in Children
NCT06751368
Aortic Regurgitation, Aortic Stenosis, Subvalvular
Beijing, Beijing Municipality, China
View Trial DetailsChina XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population
NCT03314857
Aortic Regurgitation, Aortic Stenosis
Sichuan, Chengdu, China
View Trial DetailsAortic Valve-sparing Root Replacement, According to the Inclusion Technique Described by Tirone David
NCT05515848
Aneurysm, Aortic Aneurysm
Nantes, France
View Trial Details